SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549-1004 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (date of earliest event reported): July 29, 2004 Ciphergen Biosystems, Inc. (Exact name of Registrant as specified in its charter) Delaware 000-31617 33-059-5156 (State or other jurisdiction of [Commission (I.R.S. Employer incorporation or organization) File Number] Identification Number) 6611 Dumbarton Circle Fremont, CA 94555 (Address of principal executive offices) (510) 505-2100 (Registrant's telephone number, including area code) Item 7. Financial Statements and Exhibits (c) Exhibits. 99.1 Press Release, dated July 29, 2004. Item 12. Results of Operations and Financial Condition On July 29, 2004, Ciphergen Biosystems, Inc. issued a press release announcing financial results for its fiscal second quarter ended June 30, 2004. The press release is attached as Exhibit 99.1 to this Form 8-K. The information in this Current Report is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ciphergen Biosystems, Inc. (Registrant) Date: July 29, 2004 By: /s/ William Rich ----------------------------------- William E. Rich President and Chief Executive Officer EXHIBIT INDEX Exhibit Number Description ------ ----------- 99.1 Press Release issued by Ciphergen Biosystems, Inc. on July 29, 2004